Keyphrases
Astrocytic
100%
Glia Limitans
95%
Multiple Sclerosis
84%
Visual Cortex
74%
Sham Surgery
68%
Visual Deprivation
63%
Placebo-controlled
63%
Activity-dependent Plasticity
63%
Clinical Trials
63%
Neurological Diseases
63%
Central Nervous System
57%
Blood-brain Barrier
51%
Visual Activity
47%
Anti-CD20 Therapy
46%
Perivascular Spaces
44%
Gene Expression
43%
Blood-brain Barrier Opening
40%
Astrocytes
40%
Junctional Adhesion Molecule
39%
Reactive Astrocytes
37%
Placebo
37%
Immunomodulatory Therapy
36%
Transcriptional Repressor
35%
Primary Visual Cortex V1
32%
CNS Myelination
31%
Tight Junction
31%
Gene Expression Changes
31%
Actin Binding
31%
Lateral Geniculate nucleus
31%
Immunological Response
31%
Differential Gene Expression
31%
7T MRI
31%
Central Nervous System Lesions
31%
Cell Entry
31%
Path Development
31%
Successful Treatment
31%
Auditory Pathway
31%
T Cells
31%
Gene Expression Pattern
31%
Pathways of Change
31%
Eye Dominance
31%
Sphingosine
31%
Interleukin-7 (IL-7)
31%
CD4 Lymphopenia
31%
Procedural
31%
Sham Procedure
31%
Sphingosine-1-phosphate Receptor (S1PR)
31%
Synaptic Stabilization
31%
FOXP2
31%
Glycoprotein 130 (gp130)
31%
Neuroscience
Gene Expression
95%
Visual Cortex
95%
Blood Brain Barrier
79%
Glia limitans
63%
Astrocyte
62%
Ocular Dominance
58%
Central Nervous System
47%
Nervous System Disorder
44%
Myelinogenesis
42%
Lateral Geniculate Nucleus
39%
Tight Junction
39%
Magnetic Resonance Imaging
36%
Thalamus
35%
Multiple Sclerosis
34%
Medial Geniculate Nucleus
31%
Recombinant Interleukin 7
31%
Blood Clotting Factor 6
31%
Susceptibility Weighted Imaging
31%
Parvalbumin
31%
Insulin-Like Growth Factor 1
31%
Neuroscience
31%
Auditory Cortex
31%
Placebo
31%
Actin
31%
Vasculotropin A
31%
Progressive Multifocal Leukoencephalopathy
31%
Lymphocytopenia
31%
CD4
31%
Maraviroc
31%
DNA Microarray
26%
In Vivo
24%
Immunohistochemistry
23%
Glycoprotein Gp 130
22%
Interleukin 7
22%
Growth Factor
20%
Leukocyte
15%
Synaptic Transmission
15%
Protein Binding
15%
Interneuron
15%
Parkinson's Disease
15%
Nerve Cell Degeneration
15%
Oligodendrocyte Progenitor
13%
Karyopherin
13%
G Protein
10%
Synaptic Plasticity
10%
Troponin C
10%
Transcriptome
10%
Calcium-Binding Protein
10%
JC Virus
9%
Lymphocyte
7%
Medicine and Dentistry
Placebo
63%
Clinical Trial
63%
Neurologic Disease
47%
CD20
46%
COVID-19
37%
Multiple Sclerosis
35%
Lymphocytopenia
34%
Receptor
31%
Progressive Multifocal Leukoencephalopathy
31%
Maraviroc
31%
Blood Clotting Factor 6
31%
Myelination
31%
Recombinant Interleukin 7
31%
Sphingosine
31%
Monocyte
31%
Transcriptional Activator
31%
Sham Procedure
31%
Dietary Intake
31%
Antibody Response
31%
COVID-19 Vaccine
31%
Oncology
31%
Malignant Neoplasm
31%
Sphingosine 1 Phosphate Receptor
27%
Neutralizing Antibody
23%
Glycoprotein Gp 130
22%
Interleukin 7
22%
Oligodendrocyte
18%
Disease Modifying Therapy
17%
Attitude
15%
Parkinson's Disease
15%
Clinical Trial Design
15%
Karyopherin
13%
Polymerase Chain Reaction
13%
Right to Withdraw
10%
Caloric Intake
10%
Inflammatory Disorder
10%
Anticarcinogen
10%
Maturation
9%
JC Virus
9%
Programmed Cell Death
9%
COVID-19 Vaccination
8%
Treatment Duration
8%
Sphingosine 1 Phosphate
8%
Cellular Immunity
8%
Omicron Coronavirus Variant
7%
Student T Test
7%
Placebo Effect
7%
Conditioning
7%
Humoral Immunity
6%
Teriflunomide
5%
